4-(3-chloro-4-fluorophenylamino)-6-methyl-1H-indole-2-carboxylic acid

ID: ALA4749687

Chembl Id: CHEMBL4749687

PubChem CID: 141488542

Max Phase: Preclinical

Molecular Formula: C16H12ClFN2O2

Molecular Weight: 318.74

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cc(Nc2ccc(F)c(Cl)c2)c2cc(C(=O)O)[nH]c2c1

Standard InChI:  InChI=1S/C16H12ClFN2O2/c1-8-4-13(19-9-2-3-12(18)11(17)6-9)10-7-15(16(21)22)20-14(10)5-8/h2-7,19-20H,1H3,(H,21,22)

Standard InChI Key:  IAGWIYKLCVSDPK-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4749687

    ---

Associated Targets(Human)

IDO1 Tchem Indoleamine 2,3-dioxygenase (6650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TDO2 Tchem Tryptophan 2,3-dioxygenase (1554 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 318.74Molecular Weight (Monoisotopic): 318.0571AlogP: 4.71#Rotatable Bonds: 3
Polar Surface Area: 65.12Molecular Species: ACIDHBA: 2HBD: 3
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 3.66CX Basic pKa: CX LogP: 4.35CX LogD: 1.03
Aromatic Rings: 3Heavy Atoms: 22QED Weighted: 0.65Np Likeness Score: -1.48

References

1. Cui G,Lai F,Wang X,Chen X,Xu B.  (2020)  Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.,  188  [PMID:31881488] [10.1016/j.ejmech.2019.111985]
2. Zhang Y, Hu Z, Zhang J, Ren C, Wang Y..  (2022)  Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.,  238  [PMID:35696861] [10.1016/j.ejmech.2022.114524]

Source